Q-omics provides the consensus-scored ARHGAP5 profile across patient tissues and cancer cell-line models. ARHGAP5 expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, ARHGAP5 is differentially expressed in 8, with the highest sampling consensus in KIRC. Additionally, ARHGAP5 RNA expression shows 20,673 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRC, and THYM as cancer lineages where ARHGAP5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ARHGAP5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ARHGAP5 survival associations across molecular data types. ARHGAP5 RNA expression shows survival associations in the most cancer types (28), followed by mutation status (9) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ARHGAP5 RNA expression–survival associations across cancer types. High ARHGAP5 expression shows unfavorable associations in BLCA, PAAD and UVM, but favorable associations in KIRC, UCS and LAML. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for ARHGAP5 RNA expression.
This table summarizes ARHGAP5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8, while mass-spec protein shows differences in 5. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for ARHGAP5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ARHGAP5 shows lower tumor expression in KIRC, THCA and BRCA and higher tumor expression in LIHC, CHOL and HNSC. The KIRC box plot shows higher ARHGAP5 RNA expression in normal versus tumor tissue (log2 FC = −0.877, t-test p < 0.001).
This table shows molecular features associated with ARHGAP5 in patient tissues and cancer cell lines. In patient samples, ARHGAP5 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, ARHGAP5 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and BLOOD_Leukemia.
